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Abbreviations:  
AML   acute myeloid leukemia  
CEA   carcinoembryonic antigen  
CML   chronic myeloid leukemia  
CTA   cancer-testis antigen 
CTL   cytotoxic T-lymphocyte  
HLA   human leukocyte antigen  
IFA   incomplete Freund’s adjuvant  
LAA   leukemia associated antigen  
LSC   leukemic stem cell 
MAGE  melanoma associated antigen  
MRD   minimal residual disease  
NPM1
mut
  nucleophosmin 1 gene mutation  
PASD1  Per Arnt Sim Domain containing 1  
pMHC  peptide-major histocompatibility complex 
SEREX  Serological analysis of expression cDNA libraries 
TCR   T-cell receptor  
wt   wild type 
WT1   Wilms’ tumor gene product 1 
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Abstract 
The use of peptide vaccines, enhanced by adjuvants, has shown some efficacy in clinical 
trials. However, responses are often short-lived and rarely induce notable memory responses. 
The reason is that self-antigens have already been presented to the immune system as the 
tumor develops, leading to tolerance or some degree of host tumor cell destruction. To try to 
break tolerance against self-antigens, one of the methods employed has been to modify 
peptides at the anchor residues to enhance their ability to bind major histocompatibility 
complex (MHC) molecules, extending their exposure to the T-cell receptor. These modified 
or analogue peptides have been investigated as stimulators of the immune system in patients 
with different cancers with variable but sometimes notable success. In this review we 
describe the background and recent developments in the use of analogue peptides for the 
immunotherapy of acute myeloid leukemia (AML) describing knowledge useful for the 
application of analogue peptide treatments for other malignancies. 
 
Précis  
Peptide vaccines often induce short-lived immune responses. Analogue and mutated peptides 
have been investigated to determine whether they can stimulate improved immune responses 
against wild type peptides presented on tumor cells in human leukemia. 
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Identification and classification of tumor-associated antigens 
The rationale for T-cell mediated cancer immunotherapy relies on the existence of tumor-
specific or tumor-associated antigens (TAAs) capable of generating an antigen-specific, 
cytotoxic immune response (reviewed in [1-3]). The first TAA identified was melanoma 
associated antigen (MAGE), which was identified in the early 1990s by T-cell expression 
cloning [4].  However it was the subsequent development of serological analysis of 
expression cDNA libraries (SEREX) which allowed the rapid identification of antigens from 
a range of tumor types [5]. A repository detailing more than 2,000 antigens found by this 
technique has been developed and called the cancer immunome database (http://ludwig-
sun5.unil.ch/CancerImmunomeDB/).  
Cheever et al. [6] used a three-step approach for decision making to (1) define features 
relevant for TAAs, (2) to weight those features in accordance with their practical relevance, 
and to (3) rank known TAAs using their weighted features.  Although none of the antigens 
had all of the described “ideal” features, over half were immunogenic in clinical trials, and 
nearly one-third had suggestive clinical efficacy in the "therapeutic function" category. 
Cheever’s list contained several leukemia associated antigens (LAAs) including Wilms’ 
Tumor 1 (WT1) (reviewed recently in [9]), which was identified as the most suitable antigen 
for immunotherapy. It should be noted that the weighted features described by Cheever can 
also be used to compare newly identified antigens with those in the published list. However, 
the comparison of a solid tumor and a leukemia/hematological malignancies-only list for 
ranking antigens would be of interest to the research community [7], allowing reflection on 
the different weightings of TAAs verus LAAs with a view to their application in clinical 
trials for solid and liquid tumors, respectively. It appears that many of the antigens expressed 
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with frequencies of note in solid tumors are not expressed frequently in patients with 
hematological malignancies ([7,8]), the obvious exception being WT1. 
 
Tumor antigen targets for the vaccination of AML patients 
The antigens identified in AML (and indeed most other tumor-types) can be divided broadly 
into two groups with regards to the restriction of their expression in healthy tissues. The first 
group includes cancer-testis antigens (CTAs), so called because of an expression limited to 
cancer and immunologically protected tissues, such as testis and placenta, which lack MHC 
class I expression. Examples of these include the Per Arnt Sim Domain containing 1 
(PASD1) antigen [10] and the helicase antigen (HAGE) [8]. The second grouping is that of 
the ‘TAA’ which, while expressed by tumor cells, are also found in some healthy tissues. One 
example is WT1 which is over-expressed by 10-100-fold in leukemia cells compared with 
CD34
+
 healthy hematopoietic progenitors.  Importantly, T-cells specific for a WT1-derived 
peptide/human leukocyte antigen (HLA)-A2 complex, are capable of killing WT1
+
 leukemia 
cells but not healthy WT1
+
 cells, in vitro, indicating that a disparity in antigen expression, or 
the context of presentation, can be sufficient for T-cells to discriminate between leukemic 
cells and healthy tissue [11].   
Although plenty of LAAs have been identified and several vaccination trials exist showing 
clinical and immunological responses, the break-through is still pending. One explanation is 
that the ideal target antigen has yet to be identified. In AML, the primary response to 
conventional chemotherapy is very good, but there is also a high risk of relapse. One reason 
is that the chemotherapeutic agents used are not able to eliminate chemo-resistant or 
quiescent leukemic stem cells (LSCs). It is possible to monitor minimal residual disease 
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(MRD) by real-time PCR to determine the nucleophosmin 1-mutational (NPM1
mut
) load of 
AML cells [12]. WT1 represents another molecular marker for early assessment of MRD as 
the expression levels in normal hematopoietic progenitor cells are much lower than in 
leukemic cells [13]. An ideal target for vaccination would therefore be an LAA that is highly 
expressed in LSC as well as leukemic blasts.  
 
Characteristics of peptides used in vaccination strategies 
Exposure of a peptide epitope to the immune system without the context of the whole antigen 
can be a problem. Exogenously administered antigen may not follow the same processing 
pathway as endogenously derived antigen. There are also differences in the length of a 
peptide used for vaccinations. Short peptides with a length of approximately 8 to 10 amino 
acids can bind directly to MHC class I complexes and are presented to cytotoxic T-
lymphocytes (CTLs). However peptides with a low affinity for MHC class I require de novo 
synthesized MHC and vesicular transport, while longer peptides always undergo classic or 
endosomal processing resulting in presentation, both in the context of MHC class I and II. 
Due to the omnipresence of MHC class I complexes on all nucleated cells, non-professional 
antigen-presenting cells (APCs), like fibroblasts, also present antigens to CTLs. However, 
fibroblasts do not express the co-stimulatory molecules needed for T-cell activation and 
hence, could induce immune tolerance to the presented peptide. Peptides with a length of 
more than 13 amino acids attract APCs which function by phagocytosis or macropinocytosis 
and are thus presented on MHC class II complexes.   
A common criticism of vaccination strategies aimed at single epitopes is that tumor escape 
variants can evolve during the course of the disease.  However, if vaccination results in tumor 
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lysis, numerous antigens would be released and be taken up by professional APCs, which can 
prime responses to an extended number of antigens.  This phenomenon, known as epitope 
spreading, was seen in a trial in breast and ovarian cancer patients vaccinated with dendritic 
cells pulsed with MUC-1 peptide. Vaccination resulted in the expansion of MUC-1 specific 
T-cells, as well as the gradual emergence of T-cells specific for carcinoembryonic antigen 
(CEA) and MAGE-3 [14]. 
There have been measurable successes with wild type (wt) peptide vaccines in clinical trials 
for myeloid leukemia. Several groups have developed peptide vaccines against proteinase 3, 
including the PR1 epitope, and/or WT1 which have led to both immunological and clinical 
responses against AML cells following vaccination [15-17]. However, some trials using short 
CD8
+
 peptides have been disappointing with one of the major limitations being short-lived 
immune responses due to a lack of memory T-cell induction [17-20]. The general limitations 
of peptide vaccines have led to investigations that focussed on the enhancement vaccine 
efficacy such as the use of longer peptides [21], a mixture of peptides [22] or the utilization 
of more complex adjuvants in terms of composition [23]. Alternatively, CD8
+
 peptide 
vaccines can be co-administered with class II ‘helper’ peptides [21], CpG-containing 
oligodeoxynucleotides [24] or cytokines [16,24,25].   
 
Adjuvants to enhance immunogenicity 
Simple peptide vaccines can be poorly immunogenic unless administered with a strong 
adjuvant [26] and oil-in-water formulations such as incomplete Freund’s adjuvant (IFA) are 
the commonly used as vehicles for peptides in clinical trials [16,21,24,25].  In particular, the 
combination of CpG oligos with peptide vaccines appears to be very effective. A Phase I trial 
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in melanoma patients, employing vaccination with a Melan-A peptide analogue and CpG in 
IFA, reported strong CD8
+ 
T-cell responses with more than 3% of circulating CD8
+
 T-cells 
being specific for Melan-A and only minor, transient side effects being reported [27]. Lower 
dose peptide vaccines in combination with CpG 7909 have also been shown to significantly 
increase degranulation and correlated with strengthened cytotoxicity responses in melanoma 
patients in clinical trials [28]. This is important when considered in the context of PR1 
peptide vaccination trial, which reported that only patients showing at least a doubling in the 
number of PR1 specific T-cells had clinical responses [29]. 
To increase the immunogenicity of a peptide by increasing co-stimulatory molecule 
expression and therefore T-cell activation, several adjuvants have been investigated. 
Granulocyte-macrophage colony-stimulating factor (GM-CSF) and Montanide ISA-51 (a 
water-in-oil emulsion to slow the release of antigen) are widely used adjuvants while other 
adjuvants, such as toll-like receptor agonists, are also of interest [27]. Several papers suggest 
better vaccination efficacy would occur in an environment with decreased regulatory T-cells 
numbers when a single-dose cyclophosphamide [30,31] was used. However, 
cyclophosphamide was also shown to increase the population of myeloid-derived suppressor 
cells, which are able to suppress CTL cell proliferation [32].  Interestingly, DNA 
hypomethylation agents and histone deacetylation agents (such as Decitabine and 
Azazytidine) can restore MHC class I and antigen processing machinery expression [33]. 
Interferon (IFN)- has been shown to induce MHC class I and 2-microglobulin expression 
[34]. Another axis of the immune system is that of natural killer cells being activated by 
thalidomide or lenalidomide [35]. Thalidomide was seen to enhance IL-2 production by 
CD4
+
 T-cells and enhanced cyototoxicity of natural killer cells, while the tyrosine kinase 
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inhibitor sunitinib was shown to decrease the circulation of myeloid derived suppressor cells 
and regulatory T-cells in renal cell carcinoma patients [36]. 
 
Choice of peptides: affinity, crypticity and immunodominance 
Tumor antigens are often non-mutated, wt self-proteins and as such they pose a problem for 
immunotherapy. The immune system is constantly exposed to these antigens, and, as a result, 
T-cells recognising high affinity, immunodominant epitopes may be deleted in the thymus. 
However, T-cells recognising low affinity, subdominant epitopes, may not have been deleted 
[37], and if tolerance can be overcome, may be expanded by vaccination. These expanded T-
cells could then target tumor cells which express cryptic epitopes. Cryptic epitopes are 
epitopes that are not presented, or recognized by T-cells, unless they are produced in 
unusually large concentrations, or are freed from the configuration of their native antigen 
[38]. Cryptic epitopes have been identified within several cancer associated antigens, such as 
HER-2/neu [39], human telomerase reverse transcriptase (hTERT)[39] and cytochrome P450 
1B1 [40]. Cytochrome P450 1B1 antigen is expressed in both solid and hematological 
cancers [40], and was found to be capable of expanding antitumor CTLs [41].  
Gross et al. found that the CTL repertoire in HHD mice (HHD mouse characterisation 
described in [42]) against murine telomerase reverse transcriptase (mTERT) was tolerized 
against high affinity epitopes [43]. In contrast T-cells specific for low affinity peptides were 
only mildly affected by tolerogenic control, and stimulated the expansion of high avidity, 
mTERT-specific CTLs. In addition, no signs of autoimmunity were detected in the 
vaccinated mice. The authors suggested that TERT expression in normal cells is not sufficient 
to stimulate T-cell responses against low affinity peptides, but is sufficient when presented in 
10 
 
the context of tumor cells. This could explain the lack of bone marrow toxicity in some of the 
WT1 vaccinated patients who show tumor regression. It is possible that the immune response 
has been directed against a cryptic epitope, not present in healthy bone marrow cells.    
Molldrem et al. provided evidence that tumor cells can shape the T-cell repertoire 
[19](reviewed in the context of AML in [2]).  High avidity, proteinase 3 (PR1)-specific T-
cells killed chronic myeloid leukemia (CML) cells more effectively than low-avidity T-cells 
but these cells became apoptotic when co-cultured with a high PR1 peptide concentration or 
with leukemia cells overexpressing proteinase 3. Furthermore, no high avidity T-cells could 
be detected in patients at initial presentation, whereas low avidity T-cells could be detected 
and expanded [19].   
Many peptides derived from tumor antigens are characterized by weak binding to MHC 
molecules with a resulting insufficient stimulation of antitumor immunity. This hypothesis is 
supported by studies which have shown that the MHC binding affinity of peptides can 
correlate with immunogenicity [44]. Engels et al. demonstrated that a high-affinity peptide-
MHC (pMHC) interaction led to efficient cross-presentation and was necessary to elicit T-
cell cytokine production in vivo [45]. A strong correlation between the high-affinity of the 
peptide for MHC and tumor eradication was described. Peptides with high affinities for MHC 
were effectively cross-presented by stromal cells, or cancer cells, and resulted in the secretion 
of IFN- in cognate T-cells ex vivo but this was not the case when low affinity peptides were 
used. On the basis of these studies Engels et al stated that heteroclitic peptide vaccination will 
never work because although modified peptides may induce strong T-cell responses they will 
not be able to induce tumor irradication if the native tumor antigen has a low affinity for the 
MHC. In contrast, several groups have demonstrated that the immunogenicity of peptides 
depends on MHC-binding stability rather than affinity [46,47]. Therefore, low affinity, 
11 
 
cryptic epitopes have been investigated for their potential as peptide vaccines. When supplied 
exogenously, such epitopes often fail to bind to MHC molecules for long enough, or at a high 
enough pMHC density, to efficiently stimulate CD8
+
 T-cells. 
 
Analogue peptides 
Another possibility to enhance the immunogenicity of LAAs in peptide vaccination studies is 
the use of analogue peptides with a change at one of the anchor positions. This method is 
based on the immunological synapse consisting of the MHC class I or class II complex, the 
epitope processed from the antigen, and presented on MHC, and the T-cell receptor (TCR). 
Costimulatory molecule signals ensure that the T-cells are activated and proliferate, in their 
absence T-cells become tolerant to the presented epitope despite the TCR binding to the 
pMHC. The greater the number of a given pMHC complex on the cell surface, the greater the 
chance of the corresponding TCR being engaged at the threshold level required to achieve 
activation. Peptides bind to MHC with different affinities depending on the constituent amino 
acids particularly at the anchor positions [47]. It has been shown that only one to two amino 
acids interact with the TCR and that its promiscuity allows one TCR to recognize numerous 
pMHC, thus allowing a single T-cell to be responsive to at least four distinct determinants 
within three different MHCs [48,49].  
The stability of the pMHC and hence its effectiveness at stimulating an immune response can 
be altered by changing one of the anchor residues of the epitope sequence, amino acids in 
position 2 or position 9 in the case of HLA-A2 [50,51]. Such alterations to the anchor 
residues can enhance peptide immunogenicity [44] and success of this strategy is dependent 
on the TCR binding portion of the peptide not being altered significantly by anchor residue 
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substitution. The fact that TCR recognition exhibits a degree of cross reactivity [52] makes 
this a viable approach. Peptides redesigned in this way and which induce effective T-cell 
responses are commonly referred to as ‘heteroclitic peptides’ or ‘peptide analogues’ and have 
shown efficacy in various tumor types, including chronic lymphocytic leukemia [53], CML 
[54] and AML [55].  
Chen et al. demonstrated that an analogue peptide of NY-ESO-1-SLLMWITQC (wt), with a 
single change at the amino acid in position 9, had strengthened epitope binding to the MHC 
class I complex and enhanced TCR affinity in mice [56]. Another interesting observation in 
this study was that NY-ESO-1-wt specific CTLs from analogue peptide primed mice have an 
enhanced ability to recognize target cells pulsed with the wt peptide compared to wt-specific 
T-cells from wt-peptide primed mice.  
Similar results have been reported in WT1 studies, whereby a modified WT1 peptide  
significantly enhanced the level of lysis of WT-1 expressing tumour cells by T-cells 
compared with wt peptide [57].  To circumvent tolerance, Pinilla-Ibarz et al tested analogue 
peptides for their ability to bind MHC class I and expand T-cells which could still cross-react 
with the native peptide and kill target CML cells. All peptides were made through a single 
amino acid substitution at the HLA-A*0201 binding site [58]. Subsequently, May et al. 
developed a WT1 CD4
+
 peptide epitope, 122-140, which was mutated through a substitution 
of residue 126 (arginine to tyrosine)[59]. The group demonstrated that native WT1 epitopes 
presented on the surface of human cancer cells could be recognized by CD4
+
 and WT1-
specific CTL; which were induced in response to the peptide analogue produced through the 
mutation of wt peptide. To date, most strategies have aimed to maximize the efficiency of 
peptide vaccines by focussing on pMHC binding, but the interaction between the TCR and 
pMHC complex can also be enhanced [60]. A variant of a CEA epitope, altered at the TCR 
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contact site, has been reported to cause clinical responses in colorectal cancer patients [61] 
and in myeloid leukemia TCR modified to better recognize WT1 epitopes have shown 
promising results (recently reviewed in [62]).   
 
Modified peptides characterized for use in AML clinical trials 
Examples of LAA derived modified peptides which have shown promise include: 
CD33 
Bae et al. predicted a number of modified CD33 peptides with potentially enhanced 
immunogenicity [63,64]. Their modifications, in the form of single amino acid replacement, 
were designed to increase HLA-A*0201 or TCR affinity when compared to the native CD33 
peptide. The studies concluded that the modified peptides were capable of producing highly 
cytotoxic CTLs, which were specific for both the native and modified peptide without 
inhibiting normal progenitor cells. 
WT1  
Patients whose leukemia cells showed an exceptionally high expression of WT1, exhibited a 
significantly poorer prognosis than those expressing lower levels [65], implying that WT1 is 
intimately associated with tumor progression and is therefore a particularly attractive target 
for the immunotherapy of leukemia.  To date, several HLA-A*0201-binding peptides 
(WT137-45, WT1126-134, WT1187-194 and WT1235-243) have been identified [11, 66-68] and T-cell 
populations with specificity for each of these pMHC complexes have been found in AML and 
CML patients, as well as healthy individuals.  The presence of T-cells with specificity for the 
WT1126 epitope correlates with favourable prognostic indicators in HLA-A2
+
 patients with 
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ALL and AML [69], and relatively recently this peptide was tested in a clinical setting [70].  
One of these four epitopes (WT1235-243) showed additional binding to HLA-A24, a haplotype 
common in the Far East.  However, it was noted that the sequence of this peptide contained 
only one anchor residue for HLA-A24 binding; a lysine at position 9 [57].  By substituting a 
tyrosine for a methionine at position 2, a 28-fold increase in HLA-A24-binding of the 
analogue peptide, compared with the wt peptide, was obtained.  Importantly, T-cells from 
healthy donors stimulated with the analogue peptide in vitro exhibited greater lysis of target 
cells expressing the wt peptide, compared with T-cells stimulated with the wt epitope.  A 
phase I clinical study was subsequently initiated, in which HLA-A24
+
 patients with a range 
of cancers, including AML, were vaccinated with either the wt or the modified peptide 
delivered in increasing doses (0.3-3mg), administered with Montanide ISA51 adjuvant.  
Vaccination was found to be generally safe, although the two myelodysplastic syndrome 
patients included in the study exhibited leukocytopenia.  In total, nine of the 13 patients 
showed an increase in WT1-tetramer positive T-cells following vaccination, including four of 
the five AML patients.  It should be noted that the tetramer used in this study incorporated the 
wt peptide and the presence of tetramer
+
 cells in patients immunized with the modified 
peptide, confirmed that T-cells expanded with the analogue peptide retained specificity for 
the wt peptide.  The number of patients recruited to this study precludes meaningful 
comparisons between the efficacy of the analogue and wt peptide, although it should be noted 
that significant responses were observed in patients immunized with either peptide [71].   
Identification of additional WT1-derived epitopes and modified peptide ligands continue in 
pre-clinical studies.  Pinilla-Ibarz et al. [58] showed that a modified form of WT1126-134, in 
which the first residue, an R (arginine), was replaced with a Y (tyrosine), exhibits similar 
binding to HLA-A2 as the wt epitope, yet is more efficient at expanding healthy HLA-A2
+
 T-
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cells in vitro, suggesting that this altered peptide ligand is heteroclitic. Importantly, altered 
peptide ligand-expanded T-cells lysed targets pulsed with wt peptide, as well as primary 
CML blasts.  A modified version of WT1187-195, in which the first residue (S, serine) was 
again substituted for a Y (tyrosine), exhibited improved binding to HLA-A2 and increased T-
cell expansion.  These expanded T-cells retained their ability to lyse cells expressing the wt 
peptide.  Taken together, these results showed the difficulties incurred when predicting 
altered peptide ligands; a similar substitution in two peptides designed to bind to the same 
MHC, in one case resulted in no change in MHC binding but expanded T-cells in vitro, while 
the other improved MHC binding and T-cell expansion. A panel of additional WT1-derived 
epitopes and altered peptide ligands were identified by this group, however these varied 
enormously in the availability of a suitable repertoire of T-cells, and in their efficacy at 
killing cells harbouring the wt peptide and/or an altered peptide ligand. The work highlighted 
the importance of functional assays to confirm the predictions made by algorithms.   
In a pilot study Maslak et al. delivered a polyvalent vaccine to 10 patients with AML. The 
vaccine incorporated two long WT1 CD4
+
 peptides (WT1-427 long, WT1-331 long), the 
WT1-derived peptide (WT1-A1) to stimulate CD8
+
 responses and one modified peptide 
(WT1-122A1), which can stimulate both CD4
+
 and CD8
+
 responses. As with other studies 
involving modified peptide vaccines, positive correlations were seen between administration 
of the vaccine peptide and production of CTLs. In this case, 87.5% of patients showed a 
WT1-specific T-cell response [72]. 
PASD1 
In 2013, a modified peptide for the SEREX-identified PASD1 CTA [55] was identified. The 
group had initially examined seven wt predicted epitopes for PASD1 which could bind HLA-
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A*0201 and had low similarity with other known eukaryotic proteins, but all candidates 
showed poor binding scores by SYFPEITHI or BioInformatics & Molecular Analysis Section 
(BIMAS). T2 cells were used to determine the ability of peptides to bind HLA-A2 and 
stabilize it through the detection of HLA-A2 levels on the cell surface. All wt PASD1 
peptides had negligible binding [55]. However, on modification of either the second or ninth 
amino acid to isoleucine, leucine or valine, there was a notable improvement in the binding of 
the analogue peptides. When inserted into pDOM-epitope DNA vaccines, the Pa14 analogue 
peptide was shown to stimulate IFN- secreting wt PASD1 responsive T-cells, and induce 
effective CTL responses against endogenously expressing PASD1 positive myeloid leukemia 
cells. However, no detectable T-cell response was found when T-cells were primed with the 
wt parental epitope (Pw8). 
 
Combinations of multiple peptides 
A further vaccination concept to circumvent tumor variant escape is to combine multiple 
peptides, hence answering the issue of changing peptide expression in an evolving malignant 
cell population. Although the available data is derived from experience with solid tumors 
(detailed in the following paragraph), it encompasses approaches that could be also 
transferred to hematological malignancies. 
Sampson et al. described the loss of target antigen expression in the majority of glioblastoma 
patients, with recurrence, after peptide vaccination with a 13-amino acid peptide derived from 
the EGFRvIII mutation. Whether the results were due to a downregulation of the antigen, or 
an elimination of the tumor cells that expressed the antigen, remains unclear [72]. In a 
randomized phase II trial of two multi-peptide vaccines for melanoma in the adjuvant setting, 
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one patient group received a vaccine containing a mixture of 12 peptides from melanocytic 
differentiation proteins and CTAs, compared with a group receiving a mixture of four 
melanocyte differentiation peptides [22]. It was shown that the 12-peptide vaccine induced a 
greater cumulative T-cell response than the four-peptide vaccine, as evaluated by ELISpot 
assays with lymphocytes isolated from both the peripheral blood and from the lymph node 
draining the injection site. The study also demonstrated that competition among peptides for 
MHC binding in polyvalent vaccines does not significantly inhibit T-cell induction or T-cell 
effector function. Another example of a successful multi-peptide vaccination clinical trial is a 
vaccine for renal cell cancer, IMA901, which consists of ten different tumor-associated 
peptides, that is now entering a phase III study [30].  
Interestingly, the order in which wt and modified peptides are used to vaccinate mice has 
been shown to change the avidity of CTLs by increasing the frequency of low-avidity wt 
specific CTL when a wt peptide prime was followed by a high dose modified peptide boost  
[74].  
 
Mutated epitopes (neoantigens) 
Alongside the exploitation of analogue peptides with modified anchor residues for improved 
stability of pMHC complexes or TCR binding portions, use of peptides with mutated epitopes 
as an alternative approach for immunotherapy is becoming increasingly attractive. One 
advantage of neoantigens is that high-avidity T-cells remain available to kill tumor cells [75] 
as these proteins were not presented during T-cell maturation in the thymus. This is because 
neoantigens can progress tumor development and for most leukemia patients this likely 
happens much later in the patients’ life. To date, modified peptides have been derived mainly 
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from non-mutated proteins or their non-mutated segments, however in order to preserve and 
expand T-cell populations, which can respond to neo-antigens, it would be reasonable to 
examine and target peptides with naturally mutated epitopes, where mutations would be 
tumor-associated or even tumor-specific. One example is NPM1. As a prognostic marker in 
AML, the NPM1
mut
 protein plays a special role.  Interestingly, AML patients with an 
NPM1
mut
 belong to a favorable group in the WHO classification. Mutations in the NPM1 
gene are one of the most frequent single gene mutations in AML (25%-30%) and they 
predominantly occur in AML patients with a normal karyotype (45%-60%) [76]. Although 
several mutations of the NPM1 gene exist in AML, more than 90% harbor the so-called A, B 
and D mutations [77], therefore the mutations are quite homogenous. It is now known that the 
NPM1 mutation dislocates the nuclear expression of wt protein into the cytoplasm and 
interferes with the ARF/p53 and NF-κB pathways [78]. 
The favorable prognosis of AML with NPM1
mut
 led to the hypothesis that immune responses 
may contribute to the positive outcome for patients through the specific lysis of residual 
leukemic cells that bear the NPM1
mut
. It was shown that epitopes derived from the mutated 
regions of NPM1 induced specific CD4
+
 and CD8
+
 T-cell responses. Two HLA-A2 restricted 
epitopes induced high frequencies of specific CD8
+
 T-cell responses in healthy volunteers 
and AML patients [79]. Furthermore, a survival analysis of 25 NPM1
mut
 patients, comparing 
cases with or without specific CTL responses against NPM1
mut
 epitopes, suggested a better 
overall survival of patients with specific NPM1
mut
 CTL responses [80].  
In an AML patient with NPM1
mut
 and molecular relapse, a polyspecific CTL response against 
several known LAAs, including an epitope derived from NPM1
mut
, was demonstrated after 
pre-emptive donor lymphocyte infusion [81]. Especially when considering patients harboring 
a low tumor burden, represented by MRD without hematological relapse, this subgroup 
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would be especially suited to NPM1
mut
 peptide vaccination to expand NPM1
mut–specific 
CD8
+
 T-cells and prolong remission or remove MRD. The use of analogue peptides in this 
setting has yet to be elucidated.  
 
MHC class II epitopes 
For leukemia antigens, most studies have focused on fixed anchor peptides rather than other 
sequence modifications likely due to the difficulties in successfully identifying modified 
epitopes which are immunogenic and stimulate T-cell responses against tumor bearing cells.  
In addition, the majority of research groups have chosen to study MHC class I binding 
epitopes rather than MHC class II, since the effector cells in this scenario are thought to be 
CD8
+
 T lymphocytes that recognize peptides presented on MHC class I.  Peptides are more 
promiscuous in their binding to MHC class II molecules and far more is known about the 
preferred anchor residues of MHC class I than MHC class II molecules.  It is clear that for the 
optimal induction of CD8
+
 T-cell memory, CD4
+
 T-cells are required,  therefore, simply 
vaccinating with a minimal MHC class I-binding peptide, or its altered peptide ligand, has 
been shown to be unlikely to provide long-term benefits to patients. Strategies to activate 
CD4
+
 helper T-cells have been shown to be effective in the context of DNA vaccines in 
mouse models in which the first domain of tetanus toxin is used to stimulate  CD4
+
 help 
[55,82,83] and altered WT1 peptide ligands designed for MHC class II are also being 
explored [84].   
 
Peptide vaccination and immune checkpoint modulation  
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The history of peptide vaccination using single peptides shows that the breakthrough is still 
pending. In the meantime immunotherapy with immune checkpoint inhibitors such as 
cytotoxic T-cell lymphocyte antigen 4 (CTLA-4) and programmed cell death protein 1 (PD1) 
have been very successful in different solid tumors especially in multiple melanoma [85-87].  
CTLA-4 acts as a competitive inhibitor of CD28 signaling, which due to its enhanced affinity 
for CD80/CD86, acts as a “brake” to limit immune responses. In addition CTLA-4 acts 
directly on T-cells to inhibit them. PD-1 signaling inhibits proliferation, survival and effector 
functions (such as cytotoxicity and cytokine release) in CTLs and induces apoptosis in these 
cells. PD1 silences T-cell activity by binding to the ligands PDL1 and PDL2. These two 
ligands are upregulated in response to inflammatory cytokines. PDL1 expression is 
commonly upregulated in tumor cells and PD1 expression is upregulated in tumor-infiltrating 
lymphocytes. Interestingly, the existence of neoantigens, seen where there is high mutational 
load, leads to a better response to immune checkpoint inhibitors, perhaps because there are 
higher affinity T-cells available and these are specific for neoantigens due to a lack of 
tolerance [88,89]. 
Until now, there has been no clinical trial conducted combining peptide vaccination with an 
immune checkpoint inhibitor in hematological malignancies. In stage IV melanoma, a study 
investigating a multiple MART-1 analog peptide vaccination, with or without IMP321 (a 
LAG-3Ig –lymphocyte activation gene- fusion protein), in combination with lympho-
depleting chemotherapy and adoptive transfer of autologous PBMCs was performed.  The 
vaccination in combination with the LAG-3Ig fusion protein, as an adjuvant, induced more 
robust and durable cellular antitumor immune responses [90]. A phase 3 study in patients 
with metastatic melanoma demonstrated that the addition of a glycoprotein 100 (gp100) 
peptide with ipilimumab (a CTLA-4 inhibitor) did not improve overall-survival any more 
21 
 
than ipilimumab alone, and progression-free survival was even lower in the gp100 plus 
ipilimumab treated patients [85]. In contrast, the addition of interleukin 2 to gp100 led to a 
significant improvement in progression-free survival with a trend towards prolonged median 
overall-survival compared to interleukin 2 alone [91]. 
With the introduction of immune checkpoint inhibitors into the clinic plenty of new 
possibilities for immunotherapy exist. Further clinical trials to test the optimal immune 
checkpoint inhibitors in combination with the optimal LAA have a role to play in the future.  
 
 
Summary 
It is increasingly possible to determine the phenotype of cancer stem cells and their properties 
with regards to chemotherapy, radiotherapy and possibly immunotherapy resistance 
(reviewed in [92]). Much can be learnt about cancer stem cells from AML by virtue of it 
being a cancer of (hematopoietic) stem cells and it is hoped  that ways to circumvent their 
resilience to treatment will improve survival rates in this difficult to treat disease. 
Vaccines which stimulate specific immune responses against AML have been numerous in 
vitro and donor lymphocyte infusions are one immunotherapy strategy that has been shown to 
be very effective at improving patient response rates – extending and achieving durable 
remission. However this is a balancing act against the inevitable induction of Graft versus 
Host Disease (GvHD) which can be life-limiting in some patients [93]. 
Success of the strategy of modifying epitopes to enhance anti-cancer immune responses are 
dependent on the TCR binding portion of the peptide not being altered significantly by 
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anchor residue substitution [44]. Similar modifications have led to peptide analogues which 
are effective at inducing immune responses against a range of tumor types including 
leukemia and solid tumors [54,57-59,94,95](reviewed in [96]). Despite inherent problems in 
demonstrating the ability of modified peptides to recognize and kill tumor cells, some 
heteroclitic epitopes have shown promise in phase I clinical trials [18,71,97]. Future studies 
will increasingly focus on mutated peptides that provide a cancer specific target for 
immunotherapy and the examination of overlapping peptide pools [98] to determine natural 
epitopes, that often exist at low frequencies, for future targeting. Undoubtedly, 
immunotherapy clinical trials will increasingly focus on multi-epitopes from within the same 
antigen or from different antigens in combination with immunomodulators such as CTLA4 or 
PD1 to enhance epitope spreading and minimize immune escape. This should enable the 
removal, or at the very least lead to a reduction in MRD during first remission, a state 
achieved by most patients with AML. 
Of note CD8
+
 epitopes embedded within CD4
+
 recognized sequences offer the benefit of 
inducing CD8
+
 responses in the presence of much needed CD4
+
 help. In pDOM-epitope 
DNA vaccines [55,82,83] this help is provided by the first domain of tetanus toxin which can 
induce CD4
+
 T-cell responses without subverting the tumor specificity of the vaccine. 
Translocation regions within chromosomes in AML cells may be targeted by miRNAs and 
siRNAs and provide the requisite specific targeting and AML-host cell destruction. Dendritic 
cells may also offer a powerful vehicle to present modified peptides to the immune system in 
AML patients [99]. Combination therapies which include chemotherapy to reduce tumor load 
and immunotherapy to remove MRD are expected to be superseded by conventional therapies 
used in conjunction with combination-immunotherapy protocols including the vaccination of 
patients with peptides following adoptive T-cell transfer [100] to remove residual disease. 
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Immunotherapy and our understanding of peptide vaccines continues to require further 
investigation to help this therapy reach its full potential in the clinic, ideally as part of a 
personalized therapy plan. For cancers as heterogeneous as myeloid leukemia, the cure is 
likely to need a multi-faceted and increasingly patient specific focus to maximise survival 
rates.  
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